JP2018511609A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018511609A5 JP2018511609A5 JP2017551276A JP2017551276A JP2018511609A5 JP 2018511609 A5 JP2018511609 A5 JP 2018511609A5 JP 2017551276 A JP2017551276 A JP 2017551276A JP 2017551276 A JP2017551276 A JP 2017551276A JP 2018511609 A5 JP2018511609 A5 JP 2018511609A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- binding fragment
- antigen
- administration
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 49
- 102000036639 antigens Human genes 0.000 claims description 49
- 108091007433 antigens Proteins 0.000 claims description 49
- 239000012634 fragment Substances 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 42
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims description 22
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims description 22
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims description 22
- 238000012423 maintenance Methods 0.000 claims description 20
- 102000003855 L-lactate dehydrogenase Human genes 0.000 claims description 10
- 108700023483 L-lactate dehydrogenases Proteins 0.000 claims description 10
- 230000003442 weekly effect Effects 0.000 claims description 10
- 206010018910 Haemolysis Diseases 0.000 claims description 7
- 206010022822 Intravascular haemolysis Diseases 0.000 claims description 7
- 150000001413 amino acids Chemical group 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 3
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 3
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
- 229960001230 asparagine Drugs 0.000 claims description 3
- 235000009582 asparagine Nutrition 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 229930182817 methionine Natural products 0.000 claims description 3
- 108010068617 neonatal Fc receptor Proteins 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 208000007536 Thrombosis Diseases 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 16
- 208000024891 symptom Diseases 0.000 description 6
- 230000009266 disease activity Effects 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562140711P | 2015-03-31 | 2015-03-31 | |
| US62/140,711 | 2015-03-31 | ||
| PCT/US2016/024624 WO2016160756A2 (en) | 2015-03-31 | 2016-03-29 | Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018511609A JP2018511609A (ja) | 2018-04-26 |
| JP2018511609A5 true JP2018511609A5 (enExample) | 2019-05-09 |
| JP6944375B2 JP6944375B2 (ja) | 2021-10-06 |
Family
ID=55702135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017551276A Active JP6944375B2 (ja) | 2015-03-31 | 2016-03-29 | 発作性夜間血色素尿症（ｐｎｈ）患者の亜集団の同定および処置 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20190135903A1 (enExample) |
| EP (1) | EP3277715A2 (enExample) |
| JP (1) | JP6944375B2 (enExample) |
| WO (1) | WO2016160756A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3056568B1 (en) | 2006-03-31 | 2021-09-15 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| CA2721052C (en) | 2008-04-11 | 2023-02-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| CN103328632A (zh) | 2010-11-30 | 2013-09-25 | 中外制药株式会社 | 与多分子的抗原重复结合的抗原结合分子 |
| NZ711451A (en) | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| IL278014B2 (en) | 2014-12-19 | 2023-10-01 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use |
| AR103162A1 (es) | 2014-12-19 | 2017-04-19 | Chugai Pharmaceutical Co Ltd | Anticuerpos anti-c5 y métodos para su uso |
| JP2019517473A (ja) | 2016-05-27 | 2019-06-24 | アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 難治性全身型重症筋無力症の処置のための方法 |
| LT3468990T (lt) | 2016-06-14 | 2024-06-25 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antikūnai ir jų panaudojimas |
| CN109689099B (zh) | 2016-08-05 | 2023-02-28 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
| CN110603054B (zh) * | 2017-03-06 | 2024-05-10 | 宾夕法尼亚大学理事会 | 抗c5抗体及其用途 |
| CN116271012A (zh) * | 2017-07-27 | 2023-06-23 | 瑞颂医药公司 | 高浓度抗c5抗体制剂 |
| BR112020008182A2 (pt) | 2017-10-26 | 2020-10-27 | Alexion Pharmaceuticals, Inc. | dosagem e administração de anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna (hpn) e síndrome hemolítica urêmica atípica (shua) |
| MX2020006113A (es) | 2017-12-13 | 2020-08-24 | Regeneron Pharma | Combinaciones de anticuerpos anti-c5 y usos de las mismas. |
| US12404320B2 (en) | 2018-05-31 | 2025-09-02 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients |
| JP7577542B2 (ja) | 2018-06-04 | 2024-11-05 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与 |
| JP7538723B2 (ja) | 2018-06-28 | 2024-08-22 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 抗ｃ５抗体の産生方法 |
| MX2021002710A (es) | 2018-09-06 | 2021-09-23 | Univ Pennsylvania | Anticuerpos anti-c5 humanizados y usos de los mismos. |
| WO2020092549A1 (en) | 2018-10-30 | 2020-05-07 | Alexion Pharmaceuticals, Inc. | Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| WO2007106585A1 (en) * | 2006-03-15 | 2007-09-20 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
| WO2014160129A2 (en) * | 2013-03-14 | 2014-10-02 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
| NZ711451A (en) * | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
-
2016
- 2016-03-29 US US15/560,606 patent/US20190135903A1/en not_active Abandoned
- 2016-03-29 EP EP16715720.5A patent/EP3277715A2/en not_active Ceased
- 2016-03-29 JP JP2017551276A patent/JP6944375B2/ja active Active
- 2016-03-29 WO PCT/US2016/024624 patent/WO2016160756A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018511609A5 (enExample) | ||
| JP7277649B2 (ja) | 高濃度抗ｃ５抗体製剤 | |
| JP2022141868A (ja) | 心血管リスクを低減させる方法 | |
| US20210246198A1 (en) | Methods of increasing strength and functionality with gdf8 inhibitors | |
| JP7744190B2 (ja) | リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体 | |
| JP2012525128A5 (enExample) | ||
| JP2010528047A5 (enExample) | ||
| JP2013538796A5 (enExample) | ||
| JP2020528894A5 (enExample) | ||
| JP2011504872A5 (enExample) | ||
| JP2017536414A5 (enExample) | ||
| JP2018500014A5 (enExample) | ||
| JP2018512435A5 (enExample) | ||
| JP2016528247A5 (enExample) | ||
| KR20210089214A (ko) | 항-FcRn 항체를 이용한 그레이브스 안병증의 치료 방법 | |
| EA031436B1 (ru) | Водная фармацевтическая композиция, содержащий ее предварительно заполненный шприц и применение композиции в лечении аутоиммунных заболеваний | |
| CA3181026A1 (en) | Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies | |
| JP2018529661A5 (enExample) | ||
| KR20230044312A (ko) | 보체 매개된 질환을 갖는 대상체의 염증성 시토카인 및 피로 | |
| JP2019521156A5 (enExample) | ||
| JP2017524675A5 (enExample) | ||
| US20220041694A1 (en) | Sars-cov-2 antibodies for treatment and prevention of covid-19 | |
| JP2011503094A5 (enExample) | ||
| JP2020505350A5 (enExample) | ||
| JP2009538916A5 (enExample) |